Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment

NCT00471965 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00471965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00471965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2007
Completion date
March 31, 2010
Enrollment
371 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular